STOCK TITAN

MACROGENICS (MGNX) SEC Filings, Aug 2025-Feb 2026

MGNX NASDAQ

MacroGenics, Inc. filings document a clinical-stage oncology biopharmaceutical company developing antibody-based therapeutics, including DART molecules and antibody-drug conjugates. Current reports record financial and operating results, FDA-related updates for the LINNET study of lorigerlimab, and material agreements involving ZYNYZ royalty rights under the Incyte collaboration.

Proxy and governance filings cover board elections, executive compensation, director matters and officer transitions. The filing record also addresses capital resources, collaboration and license economics, clinical-development disclosures, product-candidate updates and stockholder voting matters.

Rhea-AI Summary

MacroGenics Inc. insider activity: Sr VP, Research & CSO Ezio Bonvini reported routine equity transactions on February 7 and 8, 2026 involving restricted stock units (RSUs) and common stock of MacroGenics Inc. (MGNX).

On February 7, RSUs converting on a one-for-one basis were exercised for 7,001 shares of common stock, increasing his directly held common stock to 131,415 shares, while 2,703 shares were withheld at a price of $1.81 per share, leaving 128,712 shares directly owned. On February 8, an additional 11,166 RSUs were exercised into common stock, bringing direct common stock holdings to 139,878 shares before 4,311 shares were withheld at $1.81 per share, resulting in 135,567 directly owned common shares.

Following these transactions, Bonvini also held 13,999 RSUs from a February 7, 2025 grant of 21,000 RSUs vesting in three equal installments and 11,166 RSUs from a February 8, 2024 grant of 33,500 RSUs, also vesting in three equal installments beginning on the first anniversary of each grant date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.58%
Tags
insider
-
Rhea-AI Summary

MacroGenics, Inc. announced that Stephen Eck, M.D., Ph.D., its Senior Vice President, Clinical Development and Chief Medical Officer, will depart the company effective December 31, 2025, following a mutual agreement reached on November 14, 2025. Oversight of clinical development will be handled on an interim basis by Frank Perabo, M.D., Ph.D., Vice President, Clinical Development, while an executive recruiter conducts a search for a new Chief Medical Officer. Dr. Eck, who joined MacroGenics in July 2020 and led clinical development across multiple studies, will receive payments and benefits for a qualifying termination in accordance with his employment agreement, conditioned on a general release, waiver of claims, and compliance with his restrictive covenants.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.19%
Tags
current report
-
Rhea-AI Summary

MacroGenics (MGNX) reported that it announced financial and operating results for the quarter ended September 30, 2025. The company furnished a detailed press release as Exhibit 99.1 to this Form 8-K. The information in this report, including Exhibit 99.1, is provided as “furnished” under the Exchange Act and is not deemed “filed.”

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.84%
Tags
current report
Rhea-AI Summary

MacroGenics, Inc. reported Q3 results showing total revenue of $72.8 million versus $110.7 million a year ago, reflecting lower milestone revenue, partly offset by stronger contract manufacturing. Contract manufacturing revenue rose to $19.8 million from $4.6 million. Research and development expense declined to $32.7 million from $40.5 million.

The company generated quarterly net income of $16.8 million (basic and diluted EPS $0.27), compared with $56.3 million last year. Year to date, it recorded a net loss of $60.5 million as operating cash outflows reached $124.1 million. Cash and cash equivalents were $80.1 million with marketable securities of $66.3 million. Stockholders’ equity was $67.0 million.

In June, MacroGenics sold future ZYNYZ royalties to Sagard for $70.0 million, recognizing a liability of $70.3 million with an estimated effective interest rate of 18.6% and booked $3.3 million non-cash interest in Q3. It also recognized $50.0 million from two Sanofi regulatory milestones, included in accounts receivable at quarter end. Subsequent to quarter end, Gilead nominated a second research program and exercised its option, obligating a total of $25.0 million. Shares outstanding were 63,258,532 as of November 7, 2025. Management cites a cash runway into late 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.84%
Tags
quarterly report
-
Rhea-AI Summary

William K. Heiden, a director of MacroGenics, Inc. (MGNX), reported two open-market purchases of the company's common stock. On 08/19/2025 he purchased 50,500 shares at aggregate prices reported as $1.52 with trade prices in a range of $1.48 to $1.59, bringing his direct beneficial ownership to 61,500 shares. On 08/20/2025 he purchased an additional 49,500 shares at an aggregate price reported as $1.49 with trade prices in a range of $1.46 to $1.50, increasing his direct beneficial ownership to 111,000 shares. The Form 4 was signed by attorney-in-fact Beth A. Smith on 08/21/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.36%
Tags
insider
-
Rhea-AI Summary

Thomas Spitznagel, Sr. VP Technical Ops at MacroGenics, Inc. (MGNX), acquired 30,000 shares of common stock through the exercise of employee stock options on 08/15/2025. The options had an exercise price of $1.58 and convert to 30,000 shares upon exercise. After the reported transaction, 30,000 shares are beneficially owned directly. The option grant vests 25% one year after the grant date with the remaining 75% vesting in 12 substantially equal quarterly installments thereafter. The Form 4 was signed by an attorney-in-fact on 08/19/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
insider
Rhea-AI Summary

MacroGenics insider award: Senior Vice President and General Counsel Jeffrey Stuart Peters received an employee stock option grant for 30,000 shares on 08/15/2025. The option has an exercise price of $1.58, vests 25% after one year with the remaining 75% vesting in 12 substantially equal quarterly installments, and expires on 08/15/2035. Following the reported transaction Mr. Peters beneficially owns 30,000 common shares subject to the option on a direct basis. The Form 4 was signed by an attorney-in-fact on 08/19/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
insider
-
Rhea-AI Summary

MACROGENICS INC director Scott Koenig reported the vesting and conversion of restricted stock units (RSUs) into common shares. On 2025-08-13, a total of 52,829 RSUs (21,165 and 31,664 units) were exercised or converted into 52,829 shares of common stock at a stated price of $0.00 per share.

According to a Separation and Consulting Agreement between the company and Koenig, 50% of each outstanding and unvested RSU immediately vested, and the vested shares are to be delivered to him as soon as practicable after the vesting date. Each RSU represents a contingent right to receive one common share.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.80%
Tags
insider
-
Rhea-AI Summary

Insider option grant to CEO/Director MacroGenics reported that Eric Blasius Risser, who serves as President and CEO and a director, was granted an employee stock option covering 550,000 shares of common stock with an exercise price of $1.66. The option was granted with an exercise schedule that vests 25% one year after grant and the remaining 75% in 12 substantially equal quarterly installments thereafter. The options are exercisable through 08/13/2035 and are directly owned by the reporting person following the transaction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.80%
Tags
insider
Rhea-AI Summary

Armistice Capital, LLC and Steven Boyd report beneficial ownership of 5,960,000 shares of MacroGenics, Inc. (MGNX), equal to 9.45% of the outstanding common stock based on 63,090,323 shares outstanding as of May 9, 2025. The filing discloses that Armistice Capital, as investment manager to Armistice Capital Master Fund Ltd. (the Master Fund), and Mr. Boyd, as managing member of Armistice Capital, each have shared voting and shared dispositive power over these shares and hold no sole voting or dispositive power. The Master Fund is the direct holder and retains the right to receive dividends or sale proceeds. This is an amendment (No. 5) to the Schedule 13G filed with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.47%
Tags
other

FAQ

How many MACROGENICS (MGNX) SEC filings are available on StockTitan?

StockTitan tracks 84 SEC filings for MACROGENICS (MGNX), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for MACROGENICS (MGNX)?

The most recent SEC filing for MACROGENICS (MGNX) was filed on November 16, 2026.